期刊
MOLECULAR NEUROBIOLOGY
卷 60, 期 8, 页码 4396-4417出版社
SPRINGER
DOI: 10.1007/s12035-023-03351-6
关键词
Focal cortical dysplasia; Epilepsy; Adenosine kinase; Balloon cell; Adenosine A(2A) receptor
In this study, the adenosine signaling in FCD type I and type II patients was analyzed, revealing upregulation of adenosine-metabolizing enzymes ADK and ADA, as well as adenosine-producing enzyme CD73 in BCs. Moreover, an increase in A(2A)R density, a decrease in GLT-1 levels, and an increase in mTOR levels were observed in FCD specimens. These findings suggest that dysregulation of the adenosine system is a common pathological feature of both FCD type I and type II, and may serve as a therapeutic target for epilepsy associated with FCD.
Focal cortical dysplasia (FCD), a common malformation of cortical development, is frequently associated with pharmacoresistant epilepsy in both children and adults. Adenosine is an inhibitory modulator of brain activity and a prospective anti-seizure agent with potential for clinical translation. Our previous results demonstrated that the major adenosine-metabolizing enzyme adenosine kinase (ADK) was upregulated in balloon cells (BCs) within FCD type IIB lesions, suggesting that dysfunction of the adenosine system is implicated in the pathophysiology of FCD. In our current study, we therefore performed a comprehensive analysis of adenosine signaling in surgically resected cortical specimens from patients with FCD type I and type II via immunohistochemistry and immunoblot analysis. Adenosine enzyme signaling was assessed by quantifying the levels of the key enzymes of adenosine metabolism, i.e., ADK, adenosine deaminase (ADA), and ecto-5'-nucleotidase (CD73). Adenosine receptor signaling was assessed by quantifying the levels of adenosine A(2A) receptor (A(2A)R) and putative downstream mediators of adenosine, namely, glutamate transporter-1 (GLT-1) and mammalian target of rapamycin (mTOR). Within lesions in FCD specimens, we found that the adenosine-metabolizing enzymes ADK and ADA, as well as the adenosine-producing enzyme CD73, were upregulated. We also observed an increase in A(2A)R density, as well as a decrease in GLT-1 levels and an increase in mTOR levels, in FCD specimens compared with control tissue. These results suggest that dysregulation of the adenosine system is a common pathologic feature of both FCD type I and type II. The adenosine system might therefore be a therapeutic target for the treatment of epilepsy associated with FCD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据